IL318241A - Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer - Google Patents

Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Info

Publication number
IL318241A
IL318241A IL318241A IL31824125A IL318241A IL 318241 A IL318241 A IL 318241A IL 318241 A IL318241 A IL 318241A IL 31824125 A IL31824125 A IL 31824125A IL 318241 A IL318241 A IL 318241A
Authority
IL
Israel
Prior art keywords
inhibitors
hgf
cancer
treatment
combination
Prior art date
Application number
IL318241A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL318241A publication Critical patent/IL318241A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318241A 2022-07-08 2023-07-07 Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer IL318241A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263367949P 2022-07-08 2022-07-08
US202263370501P 2022-08-05 2022-08-05
PCT/EP2023/068862 WO2024008929A1 (en) 2022-07-08 2023-07-07 Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL318241A true IL318241A (en) 2025-03-01

Family

ID=87418784

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318241A IL318241A (en) 2022-07-08 2023-07-07 Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Country Status (11)

Country Link
US (1) US20260137681A1 (en)
EP (1) EP4551226A1 (en)
JP (1) JP2025522965A (en)
KR (1) KR20250044679A (en)
CN (1) CN119654152A (en)
AU (1) AU2023303878A1 (en)
CA (1) CA3261476A1 (en)
IL (1) IL318241A (en)
MX (1) MX2025000325A (en)
TW (1) TW202421146A (en)
WO (1) WO2024008929A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
PT3511330T (en) 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors
DK3686193T3 (en) 2011-07-27 2022-05-30 Astrazeneca Ab 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE COMPOUNDS
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
LT2964638T (en) 2013-03-06 2017-12-27 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN104230922B (en) 2013-06-19 2016-12-28 中国科学院上海药物研究所 One class five-ring heterocycles pyridine compounds and their and its production and use
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN105315259B (en) 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 Pyridine amine pyrimidine derivates, its preparation method and application
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CN111170998B (en) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 Pyrimidine or pyridine compound, preparation method and medical application thereof
AU2015360360B2 (en) 2014-12-11 2020-06-25 Beta Pharma (Shanghai) Co., Ltd. Substituted 2-anilinopyrimidine derivatives as EGFR modulators
CN107614503B (en) 2015-04-29 2020-03-10 广东众生药业股份有限公司 Fused or tricyclic arylpyrimidine compounds as kinase inhibitors

Also Published As

Publication number Publication date
CA3261476A1 (en) 2024-01-11
CN119654152A (en) 2025-03-18
JP2025522965A (en) 2025-07-17
US20260137681A1 (en) 2026-05-21
WO2024008929A1 (en) 2024-01-11
MX2025000325A (en) 2025-04-02
AU2023303878A1 (en) 2025-02-27
EP4551226A1 (en) 2025-05-14
TW202421146A (en) 2024-06-01
KR20250044679A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
PE20220807A1 (en) NEW EGFR INHIBITORS
IL317733A (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022014903A (en) EGFR TKI FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER.
MX2009002585A (en) Quinazoline based egfr inhibitors containing a zinc binding moiety.
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL173081A0 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
WO2008033748A3 (en) Quinazoline based egfr inhibitors containing a zinc binding moiety
JOP20220182A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
IL315848A (en) Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
EA201100334A1 (en) BICYCLIC DERIVATIVES OF TRIAZOLE FOR THE TREATMENT OF TUMORS
EA202192552A1 (en) OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
EP2205077A4 (en) Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
MX2020012540A (en) Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases.
IL321393A (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
IL183448A0 (en) Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
WO2004013091A3 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
MX2022008874A (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer.
EP4097140A4 (en) Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
PH12021552342A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40126841A (en) Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
HK40126792A (en) Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2010004259A (en) Improved antitumoral treatments.
MX2021013982A (en) Compound for inhibiting egfr kinase and preparation method and use thereof.
HK40085112A (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer